









Markets
/
Stocks
/
nasdaq-nuvb
/

Nuvation Bio Inc

NUVB

View Detailed Chart

2.235USD

+0.005+0.22%

Market hours （ET）Quotes delayed by 15 min

759.54MMarket Cap

LossP/E TTM



Nuvation Bio Inc

2.235

+0.005+0.22%

Overview Company Financials

Financials

Intraday

30m

Today

+0.22%

5 Days

-10.60%

1 Month

+6.94%

6 Months

-1.54%

Year to Date

-15.98%

1 Year

-33.48%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 7 analysts

BUY

Current Rating

7.167

Target Price

221.38%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

552

Total

Median

Average

Company name

Ratings

Analysts

Nuvation Bio Inc

NUVB

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Ionis Pharmaceuticals Inc

IONS

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Sell

Sell(7)

Neutral(3)

Buy(2)

Indicators

Sell(3)

Neutral(3)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.019

Neutral

RSI(14)

47.194

Neutral

STOCH(KDJ)(9,3,3)

14.723

Sell

ATR(14)

0.159

High Vlolatility

CCI(14)

-78.681

Neutral

Williams %R

77.941

Sell

TRIX(12,20)

0.736

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

2.402

Sell

MA10

2.428

Sell

MA20

2.317

Sell

MA50

2.199

Buy

MA100

2.115

Buy

MA200

2.314

Sell

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Nuvation Bio Inc. is a biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. The Company is advancing multiple clinical-stage candidates, including a ROS1 inhibitor, a mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor, a bromodomain and extra-terminal (BET) inhibitor, and a drug-drug conjugate (DDC). Its portfolio of development candidates includes taletrectinib (ROS1), safusidenib (mIDH1), NUV-868 (BET), and NUV-1511 (DDC). Taletrectinib is an oral, potent, CNS-active, selective, ROS1 inhibitor specifically designed for the potential treatment of ROS1-positive non-small cell lung cancer (NSCLC). Safusidenib is an oral, potent, targeted inhibitor of mIDH1 being evaluated in a global Phase II trial in patients with low-grade IDH1-mutant glioma. NUV-868 is a BD2-selective oral small molecule BET inhibitor, that inhibits BRD4. It is conducting Phase I/II study of NUV-1511.

Ticker SymbolNUVB

CompanyNuvation Bio Inc

CEODr. David T. Hung, M.D.

Websitehttps://www.nuvationbio.com/